Education
About Us
Working with TipRanks
Follow Us
Apimeds Pharmaceuticals US, Inc. (APUS)
:APUS
APUS Stock Chart & Stats
$2.06
-$0.04(-2.13%)
At close: 4:00 PM EDT
$2.06
-$0.04(-2.13%)
Day’s Range― - ―
52-Week Range$0.95 - $4.03
Previous CloseN/A
Volume31.35K
Average Volume (3M)104.60K
Market Cap
$25.91M
Enterprise Value$19.42M
Total Cash (Recent Filing)$6.99M
Total Debt (Recent Filing)$500.10K
Price to Earnings (P/E)―
Beta0.89
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,575,983
10 Day Avg. Volume125,814
30 Day Avg. Volume104,603
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)-18.67
Price to Sales (P/S)0.00
P/FCF Ratio-34.57
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.04K
Enterprise Value/Ebitda-3.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Apimeds Pharmaceuticals US, Inc. News
APUS FAQ
What was Apimeds Pharmaceuticals US, Inc.’s price range in the past 12 months?
Apimeds Pharmaceuticals US, Inc. lowest stock price was $0.95 and its highest was $4.03 in the past 12 months.
What is Apimeds Pharmaceuticals US, Inc.’s market cap?
Apimeds Pharmaceuticals US, Inc.’s market cap is $25.91M.
When is Apimeds Pharmaceuticals US, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Apimeds Pharmaceuticals US, Inc.’s earnings last quarter?
Currently, no data Available
Is Apimeds Pharmaceuticals US, Inc. overvalued?
According to Wall Street analysts Apimeds Pharmaceuticals US, Inc.’s price is currently Overvalued.
Does Apimeds Pharmaceuticals US, Inc. pay dividends?
Apimeds Pharmaceuticals US, Inc. does not currently pay dividends.
What is Apimeds Pharmaceuticals US, Inc.’s EPS estimate?
Apimeds Pharmaceuticals US, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apimeds Pharmaceuticals US, Inc. have?
Apimeds Pharmaceuticals US, Inc. has 12,575,983 shares outstanding.
What happened to Apimeds Pharmaceuticals US, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Apimeds Pharmaceuticals US, Inc.?
Currently, no hedge funds are holding shares in APUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Helius Medical Technologies
―
Nucana
―
Revelation Biosciences
―
Ownership Overview
64.31% Insiders
0.51% Mutual Funds
2.18% Other Institutional Investors
32.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---